JW Pharmaceutical Corporation (001065.KS)
ValueMarkers Composite Index
52% below intrinsic value ($38)
JW Pharmaceutical Corporation (001065.KS) — VMCI valuation read
001065.KS prints VMCI 66/100 inside the Healthcare sector, where the median sits at 50. The 16-point above-median delta is the cleanest single-number summary of JW Pharmaceutical Corporation's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On 001065.KS, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** 001065.KS trades at 26.0x earnings, 44% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 3.2x is the binding constraint on the bear case; that is the risk line for JW Pharmaceutical Corporation on the trailing financials.
001065.KS rose 3.7% over the trailing 7 days, with a -5.3% read on a 30-day basis.
JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.